In this patient, the diagnosis of de novo AML with mutated NPM1 was made on his first bone marrow biopsy showing 70% CD13, CD33, CD117, HLA-DR(+), and CD34(−) myeloblasts with circulating blasts and marked leukocytosis. This evidence concerns the gene KIT and Increased total leukocyte count.